A5000698463- Respiratory viral infections research
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
- Cardiomyopathy and Myosin Studies
- RNA Research and Splicing
- Muscle Physiology and Disorders
- HIV/AIDS Research and Interventions
- COVID-19 Impact on Reproduction
- Pancreatic function and diabetes
- Cellular Mechanics and Interactions
- Viral-associated cancers and disorders
- RNA modifications and cancer
- Parvovirus B19 Infection Studies
- Diabetes and associated disorders
- Metabolism, Diabetes, and Cancer
- Tissue Engineering and Regenerative Medicine
- Vaccine Coverage and Hesitancy
- HIV-related health complications and treatments
- Immune Cell Function and Interaction
- Maternal and fetal healthcare
- Gestational Diabetes Research and Management
- Tracheal and airway disorders
- Estrogen and related hormone effects
GlaxoSmithKline (United States)
2020-2025
National Cancer Institute
2006
AIDS United
2003-2005
National Heart Lung and Blood Institute
1997-2001
National Institutes of Health
1997-2001
University of Rome Tor Vergata
1991-1996
We used targeted gene disruption in mice to ablate nonmuscle myosin heavy chain B (NMHC-B), one of the two isoforms II present all vertebrate cells. Approximately 65% NMHC-B-/- embryos died prior birth, and those that were born suffered from congestive heart failure during first day. No abnormalities detected NMHC-B+/- mice. The absence NMHC-B resulted a significant increase transverse diameters cardiac myocytes 7.8 +/- 1.8 micron (right ventricle) 1.3 (left NMHC-B+/+ B+/- 14.7 1.1 13.8 2.3...
Growth cones are required for the forward advancement and navigation of growing axons. Modulation growth cone shape reorientation neurite responsible change outgrowth direction that underlies navigation. Change involves reordering cytoskeleton. Reorientation requires generation tension, which is supplied by ability to crawl on a substrate. The specific molecular mechanisms these activities unknown but thought involve actomyosin-generated force combined with linkage cell surface receptors...
Tenofovir disoproxil fumarate, a nucleotide analog HIV reverse transcriptase inhibitor with demonstrated activity against nucleoside-resistant HIV, is approved for use in adults but not children. Metabolic bone abnormalities have been seen young animals given high-dose tenofovir and HIV-infected that were treated oral fumarate. However, fumarate being used children despite lack of safety data. We hypothesized that, the higher rate turnover associated normal skeletal growth, potential...
In a phase 1/2 study, maternal respiratory syncytial virus vaccine candidate (RSVPreF3) demonstrated an acceptable safety profile and efficiently increased RSV-specific humoral immune responses in non-pregnant women.In this 2 observer-blind, placebo-controlled, randomized clinical trial (NCT04126213), the of RSVPreF3 (60 or 120 µg), administered during late second third trimester, was evaluated 213 18- to 40-year-old healthy pregnant women through 6 months postdelivery their offspring...
Abstract Ablation of nonmuscle myosin heavy chain II‐B (NMHC‐B) in mice results severe hydrocephalus with enlargement the lateral and third ventricles. All B ‐ /B died either during embryonic development or on day birth (PO). Neurons cultured from superior cervical ganglia between (E) 18 P0 showed decreased rates neurite outgrowth, their growth cones had a distinctive narrow morphology compared those normal mice. Serial sections E12.5, E13.5, E15 mouse brains identified developmental defects...
Highly active antiretroviral therapy has altered the course of HIV infection among children, but new agents are needed for treatment-experienced children with drug-resistant virus. Tenofovir disoproxil fumarate (DF) is a promising agent use in pediatric salvage therapy, because its tolerability, efficacy, and resistance profile. We designed this study to provide preliminary safety dosing information on tenofovir DF, while also providing potentially efficacious heavily treatment-experienced,...
Respiratory syncytial virus (RSV) causes respiratory tract infections, which may require hospitalization especially in early infancy. Transplacental transfer of RSV antibodies could confer protection to infants their first months life.
Background: Pregnant individuals have been historically excluded from clinical trials. To evaluate the safety of vaccines in pregnant and their infants, more data on expected ranges background rates pregnancy-related outcomes interest are needed. The objective this real-world observational study was to assess maternal, pregnancy neonatal/infant infants. Methods: We conducted a retrospective cohort infants using Kaiser Permanente Northern California January 1, 2007, December 31, 2018....
Tenofovir disoproxil fumarate (DF) is a potent nucleotide analog reverse transcriptase inhibitor approved for the treatment of human immunodeficiency virus (HIV)-infected adults. The single-dose and steady-state pharmacokinetics tenofovir were evaluated following administration DF in treatment-experienced HIV-infected children requiring change antiretroviral therapy. Using increments 75-mg tablets, target dose was 175 mg/m(2); median administered 208 mg/m(2). Single-dose 18 subjects,...
Complete ablation of nonmuscle myosin heavy chain II-B (NMHC-B) in mice resulted cardiac and brain defects that were lethal during embryonic development or on the day birth. In this paper, we report generation with decreased amounts NMHC-B. First, generated BΔI/BΔI by replacing a neural-specific alternative exon PGK-Neo cassette. This NMHC-B all tissues, including decrease 88% heart 65% compared B+/B+ tissues. developed myocyte hypertrophy between 7 months 11 age, at which time they...
Abstract Background Incidence data of respiratory syncytial virus–associated lower tract illness (RSV-LRTI) are sparse in low- and middle-income countries (LMICs). We estimated RSV-LRTI incidence rates (IRs) infants LMICs using World Health Organization case definitions. Methods This prospective cohort study, conducted 10 from May 2019 to October 2021 (largely overlapping with the coronavirus disease [COVID-19] pandemic), followed born women low-risk pregnancies for 1 year birth active...
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in childhood. Maternal immunization could help to protect infants from RSV-associated infections their first months life. We evaluated the safety, reactogenicity immunogenicity RSV maternal (RSVPreF3) vaccine candidate non-pregnant women, at different dose levels. Methods In this phase I/II, observer-blind, multicenter study (NCT03674177), healthy women aged 18–45 years were randomized...
<sec> <title>BACKGROUND</title> Maternal immunization is expected to be beneficial mothers and their infants as the antibodies induced by vaccination are transferred through placenta. To facilitate interpretation of safety data generated during studies in pregnant women infants, reliable background rates for pregnancy outcomes, pregnancy-related events interest (EIs) infant EIs critical. Pregnancy-related EIs, such preterm birth low weight, usually more common adolescent compared adult...